medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Número 11

<< Anterior Siguiente >>

Ginecol Obstet Mex 2020; 88 (11)


Preservación de la fertilidad: opinión de un grupo de expertos

Batiza RVA, Aguilar MA, Luna RRM, Pérez-Peña E, Gutiérrez GA, Ruvalcaba CLA, Salazar López-Ortiz C, Michel VJA, Shaw DRJ, Barquet MSA, Hernández LLA, García RFJ, Cortés EP, Sánchez LB, Rodríguez CR, Maldonado RI

Idioma: Español
Referencias bibliográficas: 93
Paginas: 767-805
Archivo PDF: 373.81 Kb.


RESUMEN

La preservación de la fertilidad es la aplicación de estrategias médicas y de laboratorio para cuidar la permanencia de la descendencia genética parental en adultos o niños en riesgo de esterilidad.
El cáncer es la principal indicación de preservación de la fertilidad en pacientes en edad reproductiva. Si bien en las últimas décadas se ha incrementado la incidencia de cáncer en adolescentes, los tratamientos oncológicos también han mejorado de manera importante por lo que hoy es posible la curación en un amplio porcentaje de pacientes. La mayoría de los niños y adolescentes con cáncer se convierten en supervivientes a largo plazo, lo que aumenta el interés en los efectos del tratamiento del cáncer en la fertilidad.
Los tratamientos farmacológicos para prevención del rechazo de órganos trasplantados pueden afectar la fertilidad y, por tanto, las pacientes requieren orientación para la preservación de la fertilidad.
En este documento se proponen lineamientos para la atención de pacientes oncológicas que solicitan la preservación de su fertilidad. También se consideraron casos especiales, como la preservación social en casos de conceptualización sexual diferente, y los aspectos legales y éticos básicos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pesce R, et al. Preservación de la fertilidad. Reproducción 2017; 32 (2): 34-39.

  2. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. GLOBOCAN, CA Cancer J Clin. 2018; 68 (6): 394-424. https://doi.org/10.3322/caac.21492

  3. Taylan E, Oktay K. Fertility preservation in gynecologic cancers. Gynecol Oncol. 2019; 155 (3): 522-29. doi: 10.1097/ CCO.0b013e3282a14eae

  4. Peccatori FA, et al. ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 (S6): 160-70.

  5. Cetina-Pérez L, et al. Consensus Report on the Prevention, Diagnosis, and Treatment of Cervical Cancer - a Perspective from the Immune System Toward Immunotherapy. Rev Invest Clin. 2020; 73 (3). PMID: 32488222

  6. Neerja B, et al. FIGO CANCER REPORT 2018. Cancer of the cervix uteri. Int J Gynecol Obstet 2018; 143 (S2): 22-36.

  7. National Comprehensive Cancer Network Guidelines Version 4.2019. Cervical Cancer. NCCN Evidence Blocks. 2019.

  8. Koh WJ, et al. Cervical cancer. In: Journal of the National Comprehensive Cancer Network : JNCCN. 2013; 11:320-43. http://www.ncbi.nlm.nih.gov/pubmed/23486458.

  9. Benedetti Panici P, et al. Pelvic and aortic lymphadenectomy in cervical cancer: The standardization of surgical procedure and its clinical impact. Gynecol Oncol. 2009; 113: 284-90. https://doi.org/10.1016/j.ygyno.2008.12.014

  10. Egner JR. AJCC Cancer Staging Manual. JAMA J Am Med Assoc. 2010; 304: 1726. doi:10.1001/jama.2010.1525

  11. Delgado G, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A gynecologic oncology group study. In: Gynecologic Oncology. 1990; 38: 352-7. https:// doi.org/10.1016/0090-8258(90)90072-S

  12. Lea JS, Lin KY. Cervical cancer. Obstet Gynecol Clin North Am. 2012; 39: 233-53. 10.1016/j.ogc.2012.02.008

  13. Alammari RA, et al. Impact of prior hysterectomy on surgical outcomes for laparoscopic adnexal surgery. Surg Endosc. 2020; 34(7): 2980-86. https://doi.org/10.1007/ s00464-019-07083-4

  14. Chemaitilly W, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006; 91(5):1723 – 8.

  15. Wo Jennifer Y, Viswanathan Akila N. The impact of radiotherapy on fertility, pregnancy, and neonatal outcomes of female cancer patients. Int J Radiat Oncol Biol Phys 2009; 73:1304-12.

  16. Signorello LB, et al. Female Survivors of Childhood Cancer: Preterm Birth and Low Birth Weight Among Their Children. J Natl Cancer Inst. 2006; 98(20): 1453–61.

  17. De Felice F. Fertility preservation in gynaecologic cancers. E cancer medical science. 2018; 16 (12): 798.

  18. Agarwal S, et al. Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histological subtypes. J Int Gynecol Cancer Soc. 2011; 21(1): 123-7.

  19. Hricak H, et al. American College of Radiology Imaging Network 6651; Gynecologic Oncology Group 183. Role of imaging in pre-treatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol. 2005; 23 (36): 9329-37.

  20. Zhang W, et al. Impact of pelvic MRI in routine clinical practice on staging of IB1-IIA2 cervical cancer. Cancer Managements Methods 2019; 11: 3603 -9.

  21. Selman TJ, et al. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. CMAJ. 2008; 178 (7): 855-62.

  22. Willows K, et al. Fertility-sparing management in cervical cancer: balancing oncologic outcomes with reproductive success. Gynecologic Oncology Research and Practice. 2016; 3:9.

  23. Gubbala K, et al. Outcomes of ovarian transposition in gynaecological cancers; a systematic review and metaanalysis. J Ovarian Res. 2014; 7: 69.

  24. Gómez-Pue D, et al. Tratamiento preservador de la fertilidad en adenocarcinoma de endometrio. Ginecol Obstet Mex 2011; 79 (10): 631 - 636.

  25. Ruvalcaba-Limón E, et al. Primer Consenso Mexicano de Cáncer de Endometrio Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México “GICOM”. Revista de Investigación Clínica. 2010; 62 (6): 585-605.

  26. Gupta JK, et al. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis. Acta Obstet Gynecol Scand 2002; 81 (9): 799.

  27. Clark TJ, et al. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic, quantitative review. BJOG 2002 Mar; 109 (3): 313.

  28. Soslow RA, et al. Endometrial carcinoma diagnosis: Use of FIGO grading and genomic subcategories in clinical practice: Recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2019;38 Suppl 1: S64 -S74.

  29. Schenker JG. Report of the FIGO Committee for the Study of Ethical Aspects of Human Reproduction. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1997; 57(1): 95-9.

  30. Park JY. Hysteroscopy in fertility-sparing management for early endometrial cancer: a double-edged sword. J Gynecol Oncol. 2017; 28 (1): e16.

  31. Rizzo S, et al. Endometrial cancer: an overview of novelties in treatment and related imaging key points for local staging. Cancer Imaging. 2018; 18 (1): 45.

  32. Ushijima K. Fertility sparing treatment for early stage endometrial cancer: current situation and new strategy. J Gynecol Oncol. 2019; 30 (6): e117.

  33. Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist. 2015; 20 (3): 270-8.

  34. Kalogiannidis I, Agorastos T. Conservative management of young patients with endometrial highly differentiated adenocarcinoma. Journal of Obstetrics and Gynaecology. 2011; 31 (1): 13-17.

  35. Wei J, et al. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review. Medicine (Baltimore). 2017; 96 (37): e8034.

  36. Mendonça Carneiro M, et al. Fertility-preservation in endometrial cancer: is it safe? Review of the literature. JBRA Assist Reprod. 2016; 20 (4): 232-39.

  37. Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer. 2013; 12 (2): 273-7.

  38. Topfedaisi Ozkan N, et al. Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone. J Gynecol Oncol. 2017; 28 (5): e65.

  39. Zhao J, et al. Does ovarian stimulation for IVF increase gynaecological cancer risk? A systematic review and metaanalysis. Reprod Biomed Online. 2015; 31(1): 20-9.

  40. Dahhana T, et al. Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial. Contemporary Clinical Trials. 2017; 61: 96-100.

  41. Conghui Liu, et al. Double ovarian stimulation during the follicular and luteal phase in women ≥38 years: a retrospective case-control study. Reprod Bio Med Online. 2017; (6): 678-84.

  42. Mintziori G, Goulis DG. In vitro fertilization/intracytoplasmic insemination and thyroid function: reviewing the evidence. Metabolism. 2018; 86: 44-48.

  43. Torpy JM, et al. Ovarian Cancer. JAMA. 2011; 305 (23):2484.

  44. Buys SS, et al. Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305: 2295-303.

  45. Kobayashi H, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer. 2008; 18: 414-20.

  46. Fischerova D, et al. Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. Oncologist. 2012; 17 (12): 1515-33.

  47. Lhereux S, et al. Epithelial ovarian cancer: Evolution of management in the era of precisions medicine. Ca J Clin 2019; 69: 280-304.

  48. Lisio MA, et al. High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019; 20 (4): 952.

  49. Shaaban AM, et al. Ovarian malignant germ cell tumours: cellular classification and clinical and imaging features. Radiographics. 2014; 34 (3): 777-801.

  50. Prat J. The results of conservative (fertility-sparing) treatment in borderline ovarian tumours vary depending on age and histological type. Annals of Oncology. 2014; 25 (7): 1255-58.

  51. Schultz KA, et al. Ovarian Sex Cord-Stromal Tumours. J Oncol Pract. 2016; 12 (10): 940-946.

  52. Khosla D, et al. Ovarian granulosa cell tumor: clinical features, treatment, outcome, and prognostic factors. N Am J MedSci. 2014;6(3):133-138.

  53. Mangili G, et al. Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer. 2013; 109: 29-34.

  54. Robboy SJ, et al. Robboy’s Pathology of the Female Reproductive Tract. 2nd ed. Edinburgh: Churchill Livingstone; 2008.

  55. Kurman RJ. Blaustein’s Pathology of the Female Genital Tract. 5th ed. New York: Springer; 2002.

  56. Gui T, et al. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol. 2012; 127 (2): 384-89.

  57. SSA, Consejo Nacional de Población. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Octava revisión. Colima 2019. Disponible en http://consensocancermamario. com/documentos/FOLLETO_CONSENSO_ DE_CANCER_DE_MAMA_8aRev2019a.PDF.

  58. Soto-Estrada G, et al. Panorama epidemiológico de México, principales causas de morbilidad y mortalidad. Rev. Fac. Med. (Méx.) 2016; 59 (6): 8-22.

  59. Amin MB, et al. editors. AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer, 2017.

  60. Pagani O, et al. POSITIVE: A study evaluating pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with endocrine responsive breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13). Cancer Res. 2019; 79 (S4): OT1-01-06.

  61. Dolmans M-M, et al. European recommendations for female fertility preservation (EU-REFER): a joint collaboration between oncologists and fertility specialists. Crit Rev Oncol Hematol. 2019; 138: 233-40.

  62. Donnez J, Dolmans MM. Fertility preservation in women. NEJM. 2017; 377:1657-65.

  63. Cakman H, et al. Effective method for emergency fertility preservation: random start controlled ovarian stimulation. Fertil Steril. 2013; 100(6): 1673- 1680.

  64. Abdel-Razeq H. Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer. Cancer Manag Res. 2019; 11:4273-82.

  65. Siegel RL, et al. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69 (1): 7-34. https://doi.org/10.3322/caac.21551

  66. Noone AM, et al. (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. 2018; seer.cáncer. gov/csr/1975_2015.

  67. Dirección General Adjunta de Epidemiología. Registro de Cáncer en Niños y Adolescentes. Sistema EstadísticoEpidemiológico de las Defunciones. censia. salud.gob.mx. 2015.

  68. Johnson EK, et.al. Fertility Preservation for Pediatric Patients: Current State and Future Possibilities. J Urol. 2017; 198: 186-94. https://doi.org/10.1016/j.juro.2016.09.159

  69. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010; 28: 4831-41.

  70. Hudson MM, et al. Reproductive outcomes for survivors of childhood cancer. Obstet Gynecol. 2010; 116 (5): 1171-83.

  71. Coccia PF, et al. JNCCN. 2018; 16(1): 66-97.

  72. Barton SE, et al: Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013; 14 (9): 873- 81.

  73. Green DM, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2009; 27 (16): 2677-85.

  74. Huddart RA, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005; 93 (2): 200-7.

  75. Tangir J, et al. Reproductive function after conservative surgery and chemotherapy for malignant germ celltumors of the ovary. Obstet Gynecol. 2003; 101(2): 251-7. https:// doi.org/10.1016/S0029-7844(02)02508-5

  76. Carling T, et al. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2011: 1457-72.

  77. Nelson H, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93(8):583-96. https://doi. org/10.1093/jnci/93.8.583

  78. Ries LAG, et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. 1999.

  79. Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. https://doi.org/10.1182/ blood-2016-01-643569

  80. Smith MA, et al. Declining childhood and adolescent cancer mortality. Cancer. 2014;120(16):2497-506. https://doi. org/10.1002/cncr.28748

  81. González-Ortega C, et al. Natural cycle in vitro fertilization (IVF) combined with in vitro maturation in infertile patients with polycystic ovarian syndrome (PCOS) requiring IVF. TJOG. 2019; 80: 192-95. https://doi.org/10.1016/j. tjog.2019.01.004

  82. Zhang J. Luteal phase ovarian stimulation following oocyte retrieval is it helpful for poor responders. ReprodBiol Endocrinol. 2015; 13:76. https://doi.org/10.1186/s12958- 015-0076-2

  83. Adams GP, et al. Large animal models for the study of ovarian follicular dynamics in wo men. Theriogenology. 2012; 78:1733-48. https://doi.org/10.1016/j.theriogenology. 2012.04.010

  84. Kim JH, et al. Efficacy of Random start Controlled Ovarian Stimulation in Cancer Patients. J Korean Med Sci. 2015; 30 (3): 290-95.

  85. Ubaldi FM, et al. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016; 105: 1488-95. https://doi.org/10.1016/j.fertnstert.2016.03.002

  86. Tsampras N, et al. Double ovarian stimulation (Duostim) protocol for fertility preservation in female oncology patients. Human Fertility 2017; 20 (4): 248-53. https://doi. org/10.1080/14647273.2017.1287433

  87. Shah DK, et al. Medical, ethical and legal considerations in fertility preservation. Int J Gynecol Obstet. 2011; 115: 11-15. https://doi.org/10.1016/j.ijgo.2011.05.011

  88. Condorelli M, Demeestere I. Challenges of fertility preservation in non-oncological diseases. Acta Obstet Gynecol Scand. 2019; 98 (5): 638-46. https://doi.org/10.1111/aogs.13577

  89. De Ziegler D, et al. Risk and safety management in infertility and assisted reproductive technology (ART): from the doctor’s office to the ART procedure. Fertil Steril. 2013; 100 (6): 1509-17. https://doi.org/10.1016/j.fertnstert. 2013.10.020

  90. Anchan RM, et al. Gestational carriers: A viable alternative for women with medical contraindications to pregnancy. Open J Obstet Gynecol. 2013; 3 (5B): 24-31. 10.4236/ ojog.2013.35A2005

  91. Alteri A, et al. Elective egg freezing without medical indications. Acta Obstet Gynecol Scand. 2019; 98 (5): 647-52. https://doi.org/10.1111/aogs.13573

  92. Oktay K, et al. Robot-assisted orthotopic and heterotopic ovarian tissue transplantation techniques: surgical advances since our first success in 2000. Fertil Steril. 2019; 111 (3): 604-6. https://doi.org/10.1016/j.fertnstert. 2018.11.042

  93. Martinez F. Update on fertility preservation from the Barcelona International Society for Fertility Preservation– ESHRE–ASRM 2015 expert meeting: indications, results and future perspectives. Fertil Steril. 2017; 108 (3): 407-15. https://doi.org/10.1016/j.fertnstert.2017.05.024




2020     |     www.medigraphic.com